Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DuKang Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
01
Overview
DuKang Pharmaceuticals is conducting Phase 2 trials with its lead oral GABAergic prodrug NORA520 for postpartum depression. NORA520 is also in Phase 1 for major depressive disorder, with earlier-stage programs targeting essential tremor, orphan epilepsies (e.g., Lennox-Gastaut syndrome, Dravet syndrome, CDKL5 deficiency disorder), generalized anxiety disorder, and bipolar disorder[1][8].
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on DuKang Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DuKang Pharmaceuticals.